Skip to main content

Trazimera FDA Approval History

Last updated by Judith Stewart, BPharm on Feb 27, 2020.

FDA Approved: Yes (First approved March 11, 2019)
Brand name: Trazimera
Generic name: trastuzumab-qyyp
Dosage form: for Injection
Company: Pfizer Inc.
Treatment for: Breast Cancer, Gastric Cancer

Trazimera (trastuzumab-qyyp) is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2-overexpressing breast cancer, and the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Indications and Usage

Adverse Reactions

Trazimera (trastuzumab-qyyp) is the fourth FDA-approved trastuzumab biosimilar, following the approvals for Ontruzant (trastuzumab-dttb) in January 2019, Herzuma (trastuzumab-pkrb) in December 2018, and Ogivri (trastuzumab-dkst) in December 2017.

Development timeline for Trazimera

Mar 11, 2019Approval FDA Approves Trazimera (trastuzumab-qyyp), a Biosimilar to Herceptin

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.